Medindia

X

Angelini Labopharm Announces the U.S. Launch of OLEPTRO™ for the Treatment of Major Depressive Disorder in Adults

Tuesday, August 10, 2010 Mental Health News J E 4
Advertisement
OLEPTRO™ Now Available as a New Treatment Option for MDD

For Media Inquiries (Angelini Labopharm)

For Labopharm Investor Relations Inquiries

Michael Parks

Lawrence Chamberlain

Vox Medica, Inc.

Investor Relations

Tel: (267) 885-3066

Tel:  (416) 815-0700

mparks@voxmedica.com

lchamberlain@equicomgroup.com

For Media Inquiries (Angelini)

Fabio Pieroni

Angelini Corporate Communications Director

Tel: +39 06 78053366

f.pieroni@angelini.it

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Adis Journals Make Impressive Impact Factor Gains
S
MySleepQuest.com to Help Millions Get a Good Night...